A comprehensive overview and safety evaluation of fremanezumab as a preventive therapy for migraine

ABSTRACT

Introduction: Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP mAb), is a migraine-specific treatment for migraine prevention.

Areas covered: This review will briefly discuss other available and emerging CGRP mAbs and the neurophysiology of fremanezumab. The review will focus on phase III trials of the efficacy of fremanezumab for episodic and chronic migraine, and a recent pooled safety and tolerability analysis of its use.

Expert opinion: Continued efficacy and safety data collection will help guide long-term risk and efficacy counseling in the general population.

KEYWORDS:

• CGRP
• fremanezumab
• headache
• migraine
• monoclonal antibody

Box 1. Drug summary box.

Declaration of Interest

S Parikh served as a member of a speakers bureau for Allergan. S Silberstein receives or has received honoraria as a consultant and/or advisory panel member for Abide Therapeutics, Alder Biopharmaceuticals, Allergen, Inc., Amgen, Avanir Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Cefaly, Curelator, Inc., Dr. Reddy’s Laboratories, Egalet Corporation, GlaxoSmithKline Consumer Health Holdings, LLC., eNeura Inc., electroCore Medical, LLC, Impel NeuroPharma, Inc., Lilly USA, LLC, Medscape, LLC, Novartis, Inc., Satsuma Pharmaceuticals, Supernus Pharmaceuticals, Inc., Teva Pharmaceuticals, Theranica, and Trigemina, Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer Disclosures

A peer reviewer on this manuscript has disclosed that they have received personal fees for consulting and/or lectures from Allergan, Novartis, TEVA and Lilly. All other peer reviewers on this manuscript have no relevant financial relationships or otherwise to disclose.

Additional information

Funding

This paper was not funded.